Assessing the Impact of Contraceptives on Bone Health Using 41Ca

Other Disorders of Bone Development and Growth Clinical Trial

Official title:

The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02367846
• Other study ID #: STUDY00000464
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: January 2015
• Est. completion date: December 2024

Study information

• Verified date: April 2024
• Source: Penn State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This preclinical randomized crossover study will examine the effects of oral versus non-oral contraceptive therapy on bone turnover in young exercising women. In an effort to expose the route-dependent effects of oral versus non-oral contraceptive therapy on bone turnover, the investigators will examine 1) the effects of ethinyl estradiol on bone calcium balance using the 41Ca technology and 2) the underlying physiological mechanisms associated with the effects of oral versus non-oral contraceptive therapy on net bone calcium balance.

Description:

This study is a preclinical, multi-site study (Penn State University and Purdue University) that will determine whether the negative effects of combined oral contraceptive (COC) therapy on bone turnover are dependent on the route of administration such that an attenuation of these effects is observed when a comparable dose of non-oral contraceptive therapy, such as vaginal contraceptive (CVR) therapy is also tested. Millions of women use COC therapy for birth control purposes or regulation of menstrual cycles. CVR therapy is a relatively new FDA-approved contraceptive alternative to COC. The purpose of the proposed project is to investigate whether oral ethinyl estradiol (EE) may negatively impair bone turnover when compared to vaginally-administered EE in young physically-active women.

A novel calcium tracer technology suitable to rapidly assess changes in net bone calcium balance in a small sample size will be applied to evaluate the effects of COC and CVR therapy on bone turnover. The radioisotope Calcium-41 (41Ca) demonstrates increased sensitivity when compared to dual x-ray absorptiometry (DXA) and increased specificity for bone mineralization and precision when compared to biochemical markers of bone turnover. This study will be the first study to examine how the route of estrogen administration affects bone turnover in young physically active women by assessing changes in net bone calcium balance with different forms of contraceptive therapy.

The overall purpose of this study is to explore the effects of oral versus vaginal contraceptive therapy on bone turnover in young exercising women using 41Ca technology. In an effort to expose the route-dependent effects of oral versus non-oral contraceptive therapy on bone turnover, the investigators will examine 1) the effects of ethinyl estradiol on bone calcium balance using the 41Ca technology and 2) the underlying physiological mechanisms associated with the effects of oral versus vaginal contraceptive therapy on net bone calcium balance.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 6
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 25 Years

Eligibility

Inclusion Criteria:

1. Female

2. Age 18-25 yrs

3. BMI 18-29 kg/m2

4. Non-smoking

5. Willing to refrain from using hormonal contraceptives for the equilibration + baseline period of the study (~150 days)

6. Availability to frequently visit the laboratory in the next 12 months

7. Not currently pregnant nor intending to become pregnant in the next 12 months

8. Not lactating

9. No apparent metabolic, endocrine, musculoskeletal, or severe psychiatric disease

10. Willing to maintain consistent exercise (aerobic, weight-bearing) and dietary habits during pre-intervention and intervention periods

11. Willing to refrain from supplements other than those provided by study staff in the next 12 months

12. Variable physical activity acceptable, but mode must be primarily weight bearing

13. At least 9 menses in the past 12 months

Exclusion Criteria:

1. Non-weight bearing exercise as primary mode of physical activity

2. Resistance exercise training (= 2 times 30 minutes per week of resistance exercise)

3. Complete seasonal change of impact mode of physical activity

4. Known or suspected metabolic or endocrine disease

5. Smoking

6. Pregnant

7. Currently consuming large amounts of soy products

8. Current clinical eating disorder or other axis 1 psychiatric disorder or bipolar disorders

9. Oral or hormonal contraceptive use in the last 6 months

10. Hyperparathyroidism

11. Liver or renal disease

12. Evidence of malabsorption or skeletal disorder

13. Thyroid abnormalities (controlled hypothyroidism acceptable)

14. Chronic use of non-steroidal anti-inflammatory drugs (NSAIDS)

15. Taking medications known to have interactions with oral or vaginal contraceptive therapy

16. Other Exclusion Criteria proposed by the World Health Organization COC Contraindications (Grossman et al., 2011).

Related Conditions & MeSH terms

• Bone Diseases
• Bone Diseases, Developmental
• Other Disorders of Bone Development and Growth

Intervention

Drug:
• Combined Oral Contraceptive (COC)
The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
• Contraceptive Vaginal Ring (CVR)
The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.

Locations

Country	Name	City	State
United States	Women's Health and Exercise Laboratories, The Pennsylvania State University	University Park	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Penn State University	Purdue University

Country where clinical trial is conducted

United States, 

References & Publications (4)

Denk E, Hillegonds D, Vogel J, Synal A, Geppert C, Wendt K, Fattinger K, Hennessy C, Berglund M, Hurrell RF, Walczyk T. Labeling the human skeleton with 41Ca to assess changes in bone calcium metabolism. Anal Bioanal Chem. 2006 Nov;386(6):1587-602. doi: 10.1007/s00216-006-0795-5. Epub 2006 Oct 11. — View Citation

Grossman D, White K, Hopkins K, Amastae J, Shedlin M, Potter JE. Contraindications to combined oral contraceptives among over-the-counter compared with prescription users. Obstet Gynecol. 2011 Mar;117(3):558-565. doi: 10.1097/AOG.0b013e31820b0244. — View Citation

Lee WH, Wastney ME, Jackson GS, Martin BR, Weaver CM. Interpretation of 41Ca data using compartmental modeling in post-menopausal women. Anal Bioanal Chem. 2011 Feb;399(4):1613-22. doi: 10.1007/s00216-010-4454-5. Epub 2010 Dec 9. — View Citation

Weaver CM, Martin BR, Jackson GS, McCabe GP, Nolan JR, McCabe LD, Barnes S, Reinwald S, Boris ME, Peacock M. Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology. J Clin Endocrinol Metab. 2009 Oct;94(10):3798-805. doi: 10.1210/jc.2009-0332. Epub 2009 Jul 7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in 41Ca:Ca ratio	Changes in the 41Ca:Ca ratio in 24-h urine samples measured every 10-14 days during and after oral and non-oral contraceptive therapy as determined by Accelerometer Mass Spectrometry	49 days of contraceptive therapy
Secondary	Changes in serum concentrations of insulin-like growth factor-1 (IGF-1), IGF-binding proteins (IGFBP-1, IGFBP-3), and acid labile subunit (ALS)	Changes in fasting serum concentrations of IGF-1, IGFBP-1, IGFBP-3, and ALS after oral and non-oral contraceptive therapy	49 days of contraceptive therapy
Secondary	Changes in serum concentrations of markers of bone formation and bone resorption	Changes in fasting serum concentrations of markers of bone formation (osteocalcin, P1NP) and bone resorption (CTx) after oral and non-oral contraceptive therapy	49 days of contraceptive therapy